Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CSF shunts cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (47 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 237 | 33% |
| 2020 | 0 | 171 | 36% |
| 2021 | 1 | 164 | 39% |
| 2022 | 0 | 174 | 41% |
| 2023 | 0 | 154 | 43% |
| 2024 | 0 | 134 | 45% |
| 2025 from claims | – | 116 94–136 | 46% |
| 2026 forecast | – | 118 92–148 | 46% |
| 2027 forecast | – | 119 89–158 | 47% |
| 2028 forecast | – | 121 86–167 | 47% |
| 2029 forecast | – | 123 83–176 | 47% |
| 2030 forecast | – | 124 81–184 | 48% |
Ventriculoperitoneal shunt placement and revision, including normal-pressure hydrocephalus. Professional codes (what the surgeon bills): CPT 62223, 62230.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 6 | 455−4%/yr | −4%/yr | 0.2 | 0% | 600 in 2030+4.8%/yr |
| Pennsylvania | 2 | 238−9.5%/yr | −9.5%/yr | 0.2 | 0% | 280 in 2030+2.8%/yr |
| Massachusetts | 5 | 193−8.4%/yr | −8.4%/yr | 0.2 | 0% | 220 in 2030+1.9%/yr |
| Connecticut | 1 | 129+5.9%/yr | +5.9%/yr | 0.4 | 0% | 250 in 2030+12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Aneurysm & intracranial embolization | 13 | 399+11%/yr | +11%/yr | 0.40.7× | 0% | 600 in 2030+7.1%/yr |
| Stroke thrombectomy | 15 | 346+3.2%/yr | +3.2%/yr | 0.30.7× | 0% | 330 in 2030−1%/yr |
| DBS & VNS | 4 | 206+7.7%/yr | +7.7%/yr | 0.20.7× | 0% | 280 in 2030+5.4%/yr |
CSF shunts in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
Integra LifeSciences leads with 49% of company spending on these surgeons in 2025, +6 pts on 2024.
In 2025, 4 companies reported engagement with New Jersey’s surgeons worth $34K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.